Liver Institute Northwest

Running trials

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

  NCT04951219· Phase 3· Source

• Active, not recruiting

  Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

  NCT04526665· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Source

• Active, not recruiting

  Clinical Trial Multi-analyte Blood Test

  NCT03694600· Source

• Active, not recruiting

  Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

  NCT03301506· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Primary biliary cholangitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Phase 2· Source

• Completed

  Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

  NCT06054815· Phase 2· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Source

• Completed

  Vitamin E Dosing Study

  NCT04801849· Phase 2· Source

• Completed

  A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

  NCT04880031· Phase 2· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

  NCT04454463· Source

• Completed

  A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

  NCT04439539· Phase 2· Source

• Completed

  Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT04505436· Phase 2· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Source

Trial sites

• Liver Institute Northwest18 trials
• Liver Institute Northwest, PLLC1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Primary biliary cholangitis31 works · 5 trials